Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immune (I&I) markets, including treatments for atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE) [2] - The company's lead program, APG777, targets atopic dermatitis, which is identified as the largest and least penetrated market within the I&I sector [2] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which are designed to address the limitations of existing therapies by utilizing advanced antibody engineering [2] Upcoming Events - Management of Apogee Therapeutics will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 5, 2025, at 1:00 p.m. E.T. [1] - A live and archived webcast of the event will be accessible on the company's website [1]